Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients

• Kevin T. Savage, BA,
• Monica Rosales Santillan, MD,
• Kelsey S. Flood, MD,
• Alexandra Charrow, MD, MBE,
• Martina L. Porter, MD,
• Alexa B. Kimball, MD, MPH

Affiliations

Kevin T. Savage, BA

Drexel University College of Medicine, Philadelphia, Pennsylvania

Monica Rosales Santillan, MD

Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Kelsey S. Flood, MD

Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Alexandra Charrow, MD, MBE

Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Harvard Medical School, Brigham and Women's Hospital Dermatology, Boston, Massachusetts

Martina L. Porter, MD

Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Alexa B. Kimball, MD, MPH

Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Correspondence to: Alexa B. Kimball, MD, MPH, President and CEO, Harvard Medical Faculty Physicians, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215.